Peringatan Keamanan

The primary manifestation of overdosage ranges from drowsiness to coma and symptoms may include ataxia, hypotension, hypotonia, respiratory depression which may lead to death L927.

Experimental LD50 values are as follows L928: Mouse - 780 mg/kg (intraperitoneal), 1790 mg/kg (oral), 10000 mg/kg (subcutaneous). Rat - 6250 mg/kg (intraperitoneal), 10000 mg/kg (oral), 10000 mg/kg (intraperitoneal).

Lormetazepam

DB13872

small molecule approved

Deskripsi

Lormatazepam is an orally available benzodiazepine used in the UK for the treatment of short-term insomnia L927. It is marketed by Auden Mckenzie (Pharma Division) in 0.5 and 1 mg tablet formulations.

Struktur Molekul 2D

Berat 335.185
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The terminal phase half life is 11 h [L927].
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Metabolised to an inactive metabolite via glucuronide conjugation L927

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

713 Data
Buprenorphine Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.
Hydrocodone Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.
Magnesium sulfate The therapeutic efficacy of Lormetazepam can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Lormetazepam may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.
Mirtazapine Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.
Orphenadrine Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.
Pramipexole Lormetazepam may increase the sedative activities of Pramipexole.
Ropinirole Lormetazepam may increase the sedative activities of Ropinirole.
Rotigotine Lormetazepam may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Lormetazepam.
Suvorexant Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.
Thalidomide Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Clozapine The risk or severity of adverse effects can be increased when Lormetazepam is combined with Clozapine.
Methadone Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
Phenytoin The serum concentration of Phenytoin can be increased when it is combined with Lormetazepam.
Fosphenytoin The serum concentration of Fosphenytoin can be increased when it is combined with Lormetazepam.
Sodium oxybate Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Teduglutide The serum concentration of Lormetazepam can be increased when it is combined with Teduglutide.
Ethanol Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.
Fluvoxamine The risk or severity of adverse effects can be increased when Lormetazepam is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Lormetazepam is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Lormetazepam is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Lormetazepam is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Lormetazepam is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Lormetazepam is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Lormetazepam is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Lormetazepam is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Lormetazepam is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Lormetazepam is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Lormetazepam is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Lormetazepam is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Lormetazepam is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Lormetazepam is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Lormetazepam is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Lormetazepam is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Lormetazepam is combined with Alaproclate.
Amitriptyline The risk or severity of CNS depression can be increased when Amitriptyline is combined with Lormetazepam.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Lormetazepam.
Imipramine The risk or severity of CNS depression can be increased when Imipramine is combined with Lormetazepam.
Nortriptyline The risk or severity of CNS depression can be increased when Nortriptyline is combined with Lormetazepam.
Amoxapine The risk or severity of CNS depression can be increased when Amoxapine is combined with Lormetazepam.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Lormetazepam.
Maprotiline The risk or severity of CNS depression can be increased when Maprotiline is combined with Lormetazepam.
Doxepin The risk or severity of CNS depression can be increased when Doxepin is combined with Lormetazepam.
Desipramine The risk or severity of CNS depression can be increased when Desipramine is combined with Lormetazepam.
Pizotifen The risk or severity of CNS depression can be increased when Pizotifen is combined with Lormetazepam.
Dosulepin The risk or severity of CNS depression can be increased when Dosulepin is combined with Lormetazepam.
Olanzapine The risk or severity of CNS depression can be increased when Olanzapine is combined with Lormetazepam.
Zopiclone The risk or severity of adverse effects can be increased when Lormetazepam is combined with Zopiclone.
Caffeine The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Caffeine.
Theophylline The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Theophylline.
Dyphylline The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Dyphylline.
Pentoxifylline The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Pentoxifylline.
Mercaptopurine The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Mercaptopurine.
Aminophylline The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Aminophylline.
Oxtriphylline The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Oxtriphylline.
Theobromine The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Theobromine.
Fenethylline The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Fenethylline.
8-azaguanine The therapeutic efficacy of Lormetazepam can be decreased when used in combination with 8-azaguanine.
7,9-Dimethylguanine The therapeutic efficacy of Lormetazepam can be decreased when used in combination with 7,9-Dimethylguanine.
Xanthine The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Xanthine.
7-Deazaguanine The therapeutic efficacy of Lormetazepam can be decreased when used in combination with 7-Deazaguanine.
Guanine The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Guanine.
9-Methylguanine The therapeutic efficacy of Lormetazepam can be decreased when used in combination with 9-Methylguanine.
Peldesine The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Peldesine.
Hypoxanthine The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Hypoxanthine.
9-Deazaguanine The therapeutic efficacy of Lormetazepam can be decreased when used in combination with 9-Deazaguanine.
Propentofylline The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Propentofylline.
Valomaciclovir The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Valomaciclovir.
3-isobutyl-1-methyl-7H-xanthine The therapeutic efficacy of Lormetazepam can be decreased when used in combination with 3-isobutyl-1-methyl-7H-xanthine.
Uric acid The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Uric acid.
Doxofylline The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Doxofylline.
6-O-benzylguanine The therapeutic efficacy of Lormetazepam can be decreased when used in combination with 6-O-benzylguanine.
Lisofylline The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Lisofylline.
Lobucavir The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Lobucavir.
Cafedrine The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Cafedrine.
Theodrenaline The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Theodrenaline.
Bamifylline The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Bamifylline.
Proxyphylline The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Proxyphylline.
Acefylline The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Acefylline.
Etamiphylline The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Etamiphylline.
Pentifylline The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Pentifylline.
Bufylline The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Bufylline.
Bromotheophylline The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Bromotheophylline.
Furafylline The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Furafylline.
8-chlorotheophylline The therapeutic efficacy of Lormetazepam can be decreased when used in combination with 8-chlorotheophylline.
PCS-499 The therapeutic efficacy of Lormetazepam can be decreased when used in combination with PCS-499.

Target Protein

GABA(A) Receptor GABRA1
GABA(A) Receptor Benzodiazepine Binding Site GABRA1

Referensi & Sumber

Textbook
  • ISBN: 978-0-7020-3471-8
    43. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 533-534). Edinburgh: Elsevier/Churchill Livingstone.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul